Deborah L. White

The paper introduces a probe-based workflow to detect oncogenic gene fusions in single-cell RNA-seq, validated in cancer cell lines and pediatric B-ALL cohorts.

This study shows that mitochondrial DNA mutations are linked to better responses to kinase inhibitor therapy and reduced oxidative phosphorylation in CML patients.

This study shows asciminib effectively treats NUP214::ABL1 ALL in preclinical models by inhibiting ABL1 kinase and improving survival.

This paper introduces CRISPR-PspCas13b as a method to systematically silence oncogenic fusion transcripts, showing effectiveness against drug-resistant cancer drivers.

The paper shows that chronic myeloid leukemia patients in molecular remission still have widespread aberrant alternative splicing, unlike normal gene expression and DNA methylation patterns.